Welcome to our dedicated page for Medtronic plc news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic plc stock.
Medtronic plc (NYSE: MDT) is an American medical device company with its operational and executive headquarters in Minneapolis, Minnesota, and legal headquarters in Dublin, Ireland, following its acquisition of Covidien in 2015. As one of the largest medical-device companies globally, Medtronic specializes in developing and manufacturing therapeutic medical devices for chronic diseases.
The company’s extensive product portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. It markets these products to healthcare institutions and physicians worldwide, with international sales accounting for approximately 50% of its total revenue.
In a recent announcement on April 10, 2024, Medtronic unveiled significant advancements in artificial intelligence (AI) for endoscopic care through the launch of ColonPRO™ software for the GI Genius™ intelligent endoscopy system. This new software improves polyp detection and introduces procedural highlights to enhance physicians' workflow. The company has also entered into a collaboration with Modernizing Medicine® to integrate AI-driven data with electronic health records (EHR).
Medtronic recently reported its financial results for the fourth quarter and fiscal year 2024, showcasing a global revenue of $32.364 billion, a 3.6% increase compared to the previous year. The company's revenue growth was fueled by advancements in its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios.
In addition to its financial performance, Medtronic has made strides in technological innovation. The U.S. FDA approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for chronic pain treatment, demonstrating the company’s commitment to addressing unmet clinical needs and improving patient care through advanced technologies.
Medtronic remains dedicated to its mission of alleviating pain, restoring health, and extending life, driven by a global team of over 95,000 employees across 150 countries. The company continues to leverage its diverse knowledge and insatiable curiosity to deliver innovative solutions that transform lives. For more information, visit Medtronic's official website.
Blue Yonder announced the winners of its 2024 ICONic Customer Awards during the annual Blue Yonder ICON conference on May 14, 2024, in Dallas. These awards recognize companies excelling in digital transformation of their supply chains using Blue Yonder's solutions. Notable winners include Meijer and Woolworths in Retail Renaissance, Ingredion and Coca-Cola Beverages Florida in Supply Chain Planning Resiliency, Alcon and ABINBEV in Execution Innovator, Arcadia Cold in Supply Chain Sustainability, Micron Technology and Postobón in Digital Disruptor, and Medtronic in Innovation Visionary.
Each winning company leveraged Blue Yonder’s advanced technologies to achieve significant improvements in areas like efficiency, customer satisfaction, sustainability, and forecasting. For example, Medtronic increased its statistical forecast accuracy by 13 points, and ABINBEV reduced light loads by over 80% using Blue Yonder's solutions.
Medtronic's latest technology, the MiniMedTM 780G system with Meal DetectionTM technology, is helping individuals like Jodie Snavely manage their type 1 diabetes effectively. The system automatically adjusts and corrects sugar levels every five minutes, preventing blood sugar spikes. This advancement in diabetes management technology provides peace of mind to users by maintaining stable blood sugar levels, reducing the need for constant monitoring and worry.
Medtronic plc (NYSE:MDT) will announce its financial results for the fourth quarter and full fiscal year 2024 on Thursday, May 23, 2024. The company will release summary financial information for the period ending on Friday, April 26, 2024. The results will be discussed in a video webcast at 7:00 a.m. CDT on the same day, with a replay and transcript available within 24 hours. Medtronic plans to report fiscal year 2025 results on various dates later in the year.
In a recent press release by Medtronic, Chief Scientific and Medical Officer Laura Mauri discusses the intersection of healthcare and technology in achieving longevity. While many Americans aspire to live past 90, the survey reveals a preference for a shorter, healthier life. Despite belief in healthcare technology, engagement in preventative measures remains low. Medtronic aims to bridge this gap by providing innovative solutions that enhance patient outcomes and experiences. By sharing four actions under the acronym T.E.C.H., individuals are encouraged to take charge of their health and well-being.
Medtronic's groundbreaking SMART clinical trial focusing on women with aortic stenosis marks a pivotal moment in women's health. The study compared Medtronic's Evolut transcatheter aortic heart valve system with Edwards Sapien, revealing superior performance of the Evolut system. Female-specific data from the trial sheds light on gender inequities in heart health care, emphasizing the need to address underrepresentation of women in clinical trials.
FAQ
What is the current stock price of Medtronic plc (MDT)?
What is the market cap of Medtronic plc (MDT)?
What does Medtronic plc specialize in?
Where are Medtronic’s headquarters located?
How significant are Medtronic’s international sales?
What recent advancements has Medtronic made in AI for healthcare?
What are Medtronic’s recent financial achievements?
What new technology has Medtronic introduced for chronic pain treatment?
How many employees does Medtronic have worldwide?
What is Medtronic’s mission?
Where can I find more information about Medtronic?
How does Medtronic approach innovation in healthcare?
